Celularity Inc
For the period ended Sep 30, 2023. Filed Jan 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2023 · Filed Jan 3, 2024
CELU$0.76-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)
| September 30, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $273 | $13,966 |
| Accounts receivable, net of allowance of $2,188 and $1,789 as of September 30, 2023 and December 31, 2022, respectively | 4,114 | 4,452 |
| Notes receivable | 2,072 | 2,514 |
| Inventory | 4,934 | 5,308 |
| Prepaid expenses and other current assets | 5,105 | 7,262 |
| Total current assets | 16,498 | 33,502 |
| Property and equipment, net | 70,647 | 75,655 |
| Goodwill | 7,347 | 119,694 |
| Intangible assets, net | 11,554 | 120,994 |
| Right-of-use assets - operating leases | 11,039 | 13,060 |
| Restricted cash | 14,825 | 14,836 |
| Inventory, net of current portion | 24,928 | 22,949 |
| Other long-term assets | 354 | 376 |
| Total assets | $157,192 | $401,066 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,931 | $5,810 |
| Accrued expenses and other current liabilities | 10,239 | 9,069 |
| Accrued R&D software | 24,000 | 7,333 |
| Short-term debt ($14,006 at fair value and $16,623 unpaid principal balance at September 30, 2023) | 14,006 | 37,603 |
| Other short-term debt | 2,032 | - |
| Other short-term debt - related party | 1,017 | - |
| Short-term debt - related parties | 17,949 | - |
| Deferred revenue | 2,458 | 2,273 |
| Total current liabilities | 84,632 | 62,088 |
| Deferred revenue, net of current portion | 3,099 | 2,219 |
| Acquisition-related contingent consideration | 1,606 | 105,945 |
| Noncurrent lease liabilities - operating | 26,074 | 27,985 |
| Noncurrent accrued R&D software | 7,494 | - |
| Warrant liabilities | 3,735 | 3,598 |
| Deferred income tax liabilities | 9 | 9 |
| Other liabilities | 296 | 321 |
| Total liabilities | 126,945 | 202,165 |
| Commitments and Contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2023 and December 31, 2022 | - | - |
| Common stock, $0.0001 par value, 730,000,000 shares authorized, 193,659,133 issued and outstanding as of September 30, 2023; 730,000,000 shares authorized, 148,921,187 issued and outstanding as of December 31, 2022 | 19 | 15 |
| Additional paid-in capital | 879,171 | 844,373 |
| Accumulated other comprehensive income | 2,395 | 9 |
| Accumulated deficit | (851,338) | (645,496) |
| Total stockholders’ equity | 30,247 | 198,901 |
| Total liabilities and stockholders’ equity | $157,192 | $401,066 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.